About this Initiative
The slow adoption of biosimilars in the U.S. has been attributed to various barriers, including those related to awareness, prescriber and patient concerns, limited labeling allowances for some indications, and lack of incentives to switch. To enhance adoption of biosimilars in a range of therapeutic areas, ASHP and the ASHP Foundation engaged a group of stakeholders in a coordinated initiative designed to develop a deeper understanding of current trends, understand health-system challenges and opportunities, and identify best practices learned from early adopters of biosimilars.
Furthermore, the project sought to explore pharmacists’ roles to stimulate implementation of biosimilars in a range of practice settings and therapeutic areas.The findings are presented in the Accelerating the Adoption of Biosimilars report and will be discussed in a 1-hour webinar and podcast by members of the Steering Committee.
Stimulating Adoption of Biosimilars: Report Preview
In this 1-hour activity, join expert faculty as they discuss findings from the Accelerating the Adoption of Biosimilars report. There is no CE for this activity.
Accelerating the Adoption of Biosimilars
The report aims to enhance awareness, stimulate discussion, and support broader adoption of biosimilars.